🇺🇸

Index Intelligence

· daily

S&P 500 Consumer Staples Sector SEC Filings — March 02, 2026

Across 34 diverse SEC filings labeled under S&P 500 Consumer Staples (though spanning energy, tech, biotech, REITs, media), overarching themes reveal mixed sentiment with robust revenue growth in 9/18 reporting companies averaging +18% YoY (e.g., MongoDB +27%, Helios +17% Q4), offset by declines in 6 averaging -4% YoY (Alamo -3%, Mobile Infra -4.3%) and margin compression in 7/15 cases by -130bps avg (Alamo -140bps Q4, Great Elm NAV -20% QoQ). Capital allocation shines with buybacks totaling >$430M (ADMA $200M, Proficient $15M, DiamondRock $37M past) and dividends hikes (Alamo +13.3%, Helios 116 qtrs), signaling management conviction amid $2.5B+ in M&A/debt moves (Paramount $81B, Kosmos $220M sale). Insider activity sparse but mixed at Coca-Cola Europacific (exec sales $1.4M offset by routine buys). Forward-looking data flags modest growth guidance in 6 firms (midpoints +4-7%) and catalysts like satellite launches (AST Q1 2026). Critical risks include Elevance Health CMS sanctions (Mar 31) and impairments (Kosmos $178M), while portfolio trends point to resilient cash flows (Helios record $127M FY) supporting returns. Implications: Bullish on capital return plays and growth outliers, bearish on reg/impaired names; sector shows defensive buyback trends despite macro pressures.

15 high priority 19 medium 34 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 02, 2026

Across 71 SEC filings from the USA S&P 500 Industrials stream and related sectors, overarching themes include robust M&A activity (12+ completions like ITT's $4.8B SPX FLOW acquisition and bank mergers boosting assets 20-42% YoY), strong revenue growth in energy/industrials (e.g., Venture Global +177% YoY to $13.8B, Federal Signal +17% to $2.18B), but mixed profitability with 6/15 high-materiality reports showing EPS/net income declines (avg -50% YoY). Period-over-period trends reveal YoY revenue acceleration averaging +40% in growth outperformers (10 filings >50%), offset by margin compression in 7 cases (avg -150bps, e.g., Sturm Ruger gross profit -29%), alongside positive capital returns ($500M+ buybacks/dividends across 8 firms). Critical developments: Guidance cuts (Whirlpool EPS -14% to $6), raises (Xeris +30% to $375-390M), defense hires (L3Harris/Eaton CFOs), and Phase 3 catalysts (EyePoint/Rhythm PDUFA Mar 20). Portfolio-level patterns signal industrial consolidation via M&A (ITT/Federal Signal), resilient cash flows (Tidewater FCF $426M), but watch profitability volatility and delistings (Graphjet). Market implications favor M&A plays and growth industrials, with caution on consumer/manufacturing slowdowns.

37 high priority 34 medium 71 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 02, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, key themes include proactive capital allocation with debt refinancings (Targa's $1.5B notes issuance, Peapack's $100M notes redemption), share repurchases (XOMA's $16M buyback reducing shares 5%), and M&A progress (Baker Hughes' Chart Industries merger financials filing), alongside governance resolutions (Dorchester's Nasdaq compliance fix) and mixed biotech updates (XOMA royalties ~$49-50M FY2025 prelim, Bioxytran trial). Period-over-period insights are limited but highlight XOMA's robust FY2025 royalty receipts ($22.5M Wet AMD/DME/RVO YTD, up via new 24 assets added) vs no broad YoY declines noted; energy firms show balance sheet strengthening without margin compression signals. Critical developments imply sector resilience with Targa's positive sentiment (9/10) signaling growth funding, Baker's neutral M&A advancement (7/10 materiality), and Dorchester's compliance closure reducing overhangs. Portfolio-level patterns reveal 3/7 filings with capital returns/raises (avg materiality 8.7/10), favoring bullish positioning amid stable operations. No insider selling patterns detected; forward-looking catalysts cluster in XOMA's 2026 pipeline (e.g., Seralutinib data, ersodetug approvals). Market implications: Energy players like Targa/Baker prioritize capex/deals, actionable for long positions pre-catalysts.

2 high priority 5 medium 7 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 02, 2026

Across 304 SEC filings from S&P 500 Financials and broader US equities (though heavily skewed to biotech, energy, and industrials), overarching themes include robust revenue growth averaging +25% YoY in high-materiality reporters (e.g., Venture Global +177%, Astrana Health +56%), but widespread margin compression (-100 to -200 bps average in 12/20 mixed sentiment filers like Sturm Ruger, Plug Power) and mixed profitability amid rising OpEx/R&D. Financials show shareholder-friendly capital allocation with dividend hikes (Amex +15.9%, PROG +7.7%) and buybacks (Klaviyo $500M, ADMA $200M), while biotech dominates forward-looking catalysts (20+ Phase 2/3 readouts H1-H2 2026). M&A activity surges (30+ deals, e.g., Warner Bros $81B, Malibu Boats accretive), insider conviction mixed (Coca-Cola exec sales $1.4M but small buys), and guidance largely raised (e.g., Lumexa +3-8%, Xeris +30%). Portfolio-level trends: 65/304 positive sentiment, revenue YoY up in 180/304, but net losses in 40% due to impairments/restructurings; net leverage improving in 15 BDCs/REITs (avg 1.5-3x). Implications: Bullish for growth sectors with catalysts, cautious on margins/expenses; actionable now on dividend payers and H1 biotech events.

125 high priority 179 medium 304 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 02, 2026

Across the 8 S&P 500 Technology stream filings dated around March 2, 2026, dominant themes include aggressive capital returns via share repurchases in software firms (Klaviyo $500M program + $100M ASR imminent; Synopsys $250M ASR), signaling strong management conviction amid neutral governance changes (Datadog board expansion, Broadcom director retirement). Intuitive Surgical's completion of a key acquisition enhances its distribution footprint, while Murphy USA (outlier retail) reports mixed 2025 results with EBITDA up slightly YoY to $1.02B from $1.01B but fuel volumes down 3.0% YoY and OpEx up 5.8% to $763M, issuing cautious 2026 guidance for continued fuel declines (-3.0% to -1.0%). ACNB's note redemption and C2 Blockchain's micro-equity raise highlight debt management and dilution risks in non-core names. Portfolio-level trends show 2/8 companies pursuing major buybacks (positive for EPS accretion), limited YoY growth visibility except Murphy's flat contributions, and forward catalysts like ASR settlements and redemptions creating near-term volatility. Overall sentiment leans positive from capital allocation (3 positive filings) but mixed ops signal sector resilience with pockets of pressure; investors should prioritize buyback initiators for alpha amid low M&A disclosure.

2 high priority 6 medium 8 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 02, 2026

Across these 6 NASDAQ-100 filings dated March 2, 2026, overarching themes include strategic expansions in AI/security (AITX), resilient retail operations amid headwinds (Murphy USA), board governance refreshes (CCC, Broadcom), biotech capital access (Intellia), and M&A completion in robotics (Intuitive Surgical), with 5/6 filings carrying positive sentiment versus one mixed. Key period-over-period trends highlight Murphy USA's Adjusted EBITDA up slightly YoY to $1.02B from $1.01B despite -3.0% same-store fuel volume decline and +5.8% store OpEx to $763M, marking an outlier in detailed financial disclosures while others focus on non-financial catalysts. Critical developments like Intellia's 38% ATM capacity expansion to $1.035B and Intuitive's acquisition closure signal funding flexibility and market penetration, but Murphy's FY2026 guidance flags ongoing -3.0% to -1.0% fuel volume declines. Portfolio-level patterns show tech/AI firms pursuing partnerships and audits for credibility (AITX SOC 2), contrasting retail's flat fuel contribution amid competition from 600+ new stores since 2020. Overall, bullish operational momentum in 4/6 companies supports near-term upside, tempered by retail sector pressures.

3 high priority 3 medium 6 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 02, 2026

Across 92 SEC filings from Dow Jones 30-related and blue-chip streams dated March 2, 2026, dominant themes include robust revenue growth in energy/LNG (e.g., Venture Global +177% YoY to $13.8B) and biotech (e.g., Xeris +43.7% FY revenue), offset by mixed results in cruises and E&P with margin pressures; banking sector shows aggressive M&A consolidation (7+ deals adding billions in assets). Period-over-period trends reveal 18/92 companies with >30% YoY revenue growth (avg +65%), but 12/92 reported net losses or impairments amid higher expenses; capital allocation leans bullish with 9 dividend hikes (e.g., Amex +16%) and 5 buyback expansions (e.g., Klaviyo $500M). Insider activity is sparse but mixed (Coke PDMR sales $1.4M countered by buys), while forward guidance is raised in 15 cases (e.g., Dave 25-28% revenue growth). M&A activity surges (12 deals, e.g., Warner Bros $31/share cash merger), signaling portfolio optimization, but regulatory risks loom (Elevance CMS sanctions). Overall, bullish momentum in healthcare/tech/energy supports DJ30 outperformance, with banking M&A as a key alpha driver amid 5.3x avg net leverage stability.

45 high priority 47 medium 92 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 02, 2026

Across 51 filings in the S&P 500 Consumer Discretionary intelligence stream (with heavy financial services overlap), Q4/FY2025 results show mixed performance: 6/10 reporting companies experienced YoY revenue declines averaging -12% (e.g., Core Scientific -16%, Crawford -11%, Mobile Infra -4.3%), driven by weather disruptions, lower claims/volumes, and transients, while outliers like Life360 (+32% revenue) and Riot Platforms (+72%) posted strong growth. Bank/financial M&A dominated with 8 completions (e.g., HBT Financial, Farmers National, First Mid) boosting assets 30-42% on average, signaling consolidation. Capital allocation remains shareholder-friendly: 5 buyback/dividend hikes (Proficient $15M repurchase, WhiteHorse insiders bought $8M shares), but insider sales in CCE (execs sold $1.4M) flag caution. Forward guidance stable (Mobile Infra +4-7% 2026 rev/NOI growth), with power expansions (Core Scientific +730MW) and venue reopenings as catalysts. Portfolio trend: margin volatility (gross margins expanded in Life360 +3pp, compressed elsewhere), liquidity strong ($1.9B Riot, $533M Core), but restatements (Core Scientific) and debt rises (TPG 2.14x to 3.0x) add risks. Implications: Favor M&A beneficiaries and growth outliers for upside, monitor weather-sensitive ops.

22 high priority 29 medium 51 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 02, 2026

Across 35 filings in the USA S&P 500 Healthcare stream (with broader market exposure including biotechs, insurers, banks, and others), overarching themes include robust biotech pipeline advancements and financings (e.g., NewAmsterdam's Phase 3 successes, Zymeworks' $250M royalty deal), active M&A/integration (9 deals like HBT Financial, Rallybio, Intuitive Surgical), steady capital returns via buybacks/dividends (Tidewater $500M auth, Stewart $0.525/share), but mixed financials with 6/12 reporting entities showing YoY revenue declines (avg -15%, e.g., Core Scientific -16%, Zymeworks Q4 -92%). Healthcare-specific trends highlight positive clinical catalysts (NewAmsterdam 35-40% LDL-C reduction, Tyra data readouts 2026) offset by insurer risks (Elevance CMS sanctions threat), while period comparisons reveal biotech net losses widening (Tyra FY +39% to $119.9M) amid R&D ramps (+27-29% YoY). Insider activity mixed with sales at Coca-Cola Europacific ($1.41M total) but routine buys; capital allocation favors deleveraging (Peapack $100M redemption) and repurchases. Portfolio implications: overweight biotechs with 2026 catalysts, monitor insurer regulatory overhangs for near-term volatility.

14 high priority 21 medium 35 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — February 27, 2026

Across 35 SEC filings from the USA S&P 500 Consumer Staples intelligence stream (though spanning diverse sectors like utilities, materials, and consumer discretionary), a cluster of 10+ earnings-related 8-Ks (Items 2.02/7.01) signals active Q4/FY2025 reporting season with neutral sentiment dominating; period-over-period trends reveal mixed performance including HEI's dramatic NI turnaround from -$1.4B to +$123M YoY, UAMY record Q3/9M revenues, PNW 9 consecutive quarters of 4-6.8% sales growth, but sales declines at Callaway (-1.9% H1 2025), Yelp Q4 (-1% YoY), and Elite Express widened losses despite +9.1% FY2025 revenue. Forward-looking highlights include PNW raised sales/EPS guidance to 5-7% CAGR through 2030, Yelp 2026 revenue outlook $1.455-1.475B, and UAMY expansions (smelters to 300tpm, Alaska exploration May 2026). Capital allocation shows UAMY strong $90-92M cash for growth, Wyndham $650M notes to repay debt, but risks emerge from accounting issues (Elauwit non-reliance, MPWR $195M restatement) and unknown material agreements (Ultra Clean, KORE). Portfolio-level patterns: margin resilience in Callaway op income +7.2% H1 despite sales drop, SPAC IPO surge (Clearthink $125M, MOZAYYX upsized $261M), neutral insider activity with no major buys/sells flagged; actionable theme is monitoring restatements and guidance for staples-adjacent consumer names amid broader market rotations.

12 high priority 23 medium 35 total filings
· daily

S&P 500 Industrials Sector SEC Filings — February 27, 2026

Across 56 filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, machinery, transportation despite some pharma/bank crossovers), dominant themes include a surge in Q4 2025 earnings disclosures (25+ Item 2.02 filings, neutral sentiment, no widespread quant trends disclosed), proactive capital raises/debt refinancings ($200M-$800M tranches in 8 filings for capex/acquisitions), and governance/M&A milestones (board changes, shareholder votes, mergers approved). Period-over-period insights are sparse but highlight revenue growth outliers like IPST (+53-60% QoQ Q4 revenues to $4.6-4.8M, +17-23% FY YoY) offset by massive losses from token markdowns, and Pathfinder Bancorp narrowing FY2025 net loss to $1.9M (-44% YoY improvement). Financing activity signals liquidity bolstering amid neutral sector sentiment (48/56 neutral), with positive outliers in refis (Advanced Drainage $750M revolver, GE HealthCare $500M facility) implying stable balance sheets. No insider trading patterns detected; capital allocation leans toward debt/equity for growth vs dividends/buybacks. Portfolio-level: watch for earnings call catalysts as 20+ filings attach exhibits without disclosed metrics, potential for margin/revenue reveals; industrials show resilience via refis but mixed execution in adjacent sectors.

21 high priority 35 medium 56 total filings
· daily

S&P 500 Financials Sector SEC Filings — February 27, 2026

Across 241 SEC filings from S&P 500 Financials on Feb 27, 2026, overarching themes include mixed earnings with revenue growth in insurers (AXIS GPW +7% YoY to $9.6B) and turnarounds (HEI FY net income $123M from -$1.4B loss, core +20%), but declines in REITs/hotels (Apple Hospitality RevPAR -1.6% YoY FY2025, EBITDA margin -190bps to 34.3%) and occupancy pressures (Saul Centers commercial 94.6% down from 95.2%). Capital allocation robust with AXIS >$1B returns, Apple $58.3M buybacks (4.6M shares), Healthcare Realty $50M repurchases; financings prevalent (Wyndham $650M notes, Tandem $200M convertibles). Delisting risks cluster in small caps (Datavault, reAlpha, Envoy), while M&A catalysts emerge (Carnival DLC unification April 17 vote, FirstSun/First Foundation approvals). Forward guidance positive in pockets (Gogo 2026 rev $905-945M +FCF $90-110M, Healthcare Realty SS NOI 3.5-4.5%). Sentiment mixed (positive 20%, bearish 10%), with portfolio-level trends showing avg revenue +5-10% YoY in winners but -1-5% in laggards, implying selective rotation to insurers/strong balance sheets amid financing/debt trends.

107 high priority 134 medium 241 total filings
· daily

S&P 500 Technology Sector SEC Filings — February 27, 2026

Across these 10 S&P 500 Technology stream filings dated Feb 27, 2026, disclosures are predominantly neutral with limited quantitative enriched data, featuring sparse period-over-period trends dominated by Apple Hospitality REIT's (APLE) FY2025 revenue decline of 1.1% YoY and EBITDA margin contraction of 190 bps to 34.3%, alongside Q4 RevPAR drop of 2.6% YoY. Governance events prevail, including a DNOW board member opting not to reelect (no disagreement), Jewett-Cameron AGM with significant shareholder opposition to executive comp (611,957 against votes), and compensatory arrangements at Smurfit Westrock and Iridium Communications. Forward-looking elements include APLE's preliminary Jan 2026 RevPAR down ~1.5% YoY, Intuitive Machines' SEC registration deadline of April 1, 2026, and Iridium's Q1 2026 10-Q for comp plan exhibits. Capital allocation highlights APLE's 4.6M share repurchase for $58.3M and strong balance sheet (35% net debt to cap). Sentiment is neutral in 8/10 filings, mixed in APLE and Jewett due to softening demand offset by buybacks and passed resolutions despite opposition. Portfolio-level implication: low materiality overall (avg 5.2/10), signaling stable but unexciting tech-adjacent operations with watch for dilution risks from registrations and governance pushback.

4 high priority 6 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — February 27, 2026

The 15 NASDAQ-100 8-K filings dated February 27, 2026, are dominated by earnings-related disclosures (TXNM Energy, NIQ Global Intelligence, Alpha Metallurgical x2) under Items 2.02/7.01 without specific metrics, suggesting quiet period filings ahead of full reports with high materiality (avg 7/10). Netflix's termination of the WBD merger yielded a $2.8B fee, a major cash positive offsetting lost streaming assets amid media M&A volatility. Apple Hospitality REIT disclosed FY2025 results with revenue down 1.1% YoY to $1.4B, RevPAR -1.6% YoY to $117.95, Q4 EBITDA -8.4%, and Jan 2026 RevPAR -1.5%, but countered with $58.3M buybacks and 35% net debt-to-cap. Governance events include Comcast's audit committee addition, Smurfit Westrock officer comp changes, Iridium incentive plans, and Jewett-Cameron's AGM with strong opposition to exec comp (612k against votes). Limited period-over-period data highlights hospitality weakness as the sole quantitative trend, contrasting neutral-to-mixed sentiment portfolio-wide. Amazon's undisclosed material agreement and Intuitive Machines' registration rights add opacity-driven catalysts. Overall, neutral backdrop with actionable cash (Netflix), buybacks (APLE), and exhibit-dependent earnings insights.

6 high priority 9 medium 15 total filings
· daily

Dow Jones 30 Stocks SEC Filings — February 27, 2026

Across 84 SEC filings from February 27, 2026, primarily 8-Ks, a dominant theme is the kickoff of Q4/FY2025 earnings season with 20+ Item 2.02 disclosures (e.g., AXIS Capital, BrightSpring, Delek US), revealing mixed period-over-period trends: revenue growth in insurance (AXIS +7% YoY GPW to $9.6B) contrasted with declines in REITs/hospitality (Apple Hospitality -1.1% YoY revenue, -1.6% RevPAR) and media (Warner Bros Discovery -5% YoY revenue to $37.3B). Capital allocation shines with $1B+ returns at AXIS, Apple Hospitality's 4.6M share buyback ($58.3M), and debt reductions (Fold Holdings extinguished $66.3M notes, Presurance $14M rights proceeds). Forward-looking catalysts cluster around M&A (Carnival DLC unification vote April 17, FirstSun merger approved, Warner Bros Discovery $81B acquisition by PSKY closing Q3 2026) and clinical trials (NeOnc March 4 call). Bearish outliers include delistings (Datavault AI, Envoy Medical, Avidity Biosciences implied), biotech setbacks (Aardvark trial pause, Disc Medicine 20% workforce cut), and distressed financing (IMAC 28.6% discount note). Portfolio-level patterns show resilient financials/insurance vs. pressured consumer-facing (hotels down RevPAR -1.5-2.6% YoY) amid no broad insider selling but neutral board churn; actionable now: favor capital returners, avoid delisting risks.

36 high priority 48 medium 84 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — February 27, 2026

Across 50 filings in the S&P 500 Consumer Discretionary intelligence stream (with broader SEC captures), neutral sentiment dominates (70%+ filings) amid frequent board/officer changes and undisclosed Reg FD items, but mixed earnings reveal revenue declines averaging -4% YoY where reported (e.g., Where Food -3.3% FY2025, Topgolf Callaway -1.9% H1 2025) offset by margin gains (Topgolf +150 bps Q1 gross margin) and operating income growth (Topgolf +7.2% H1). Key CD highlights include Amazon's undisclosed material agreement (materiality 8/10), Netflix's $2.8B termination fee from failed WBD acquisition (materiality 10/10), and Avis Budget's resolving shareholder suits. Portfolio trends show positive capital allocation via buybacks ($858M FTI, 183k shares Where Food), debt cleanups (Fold $66.3M extinguished), and issuances ($600M HA, $200M PennantPark), signaling financial flexibility despite no insider trading patterns disclosed. M&A resolutions (First Foundation/FirstSun approvals, Netflix termination) build a catalyst calendar into Q2 2026, implying sector resilience in entertainment/retail but caution on growth amid losses (Sable $410M FY2025). Actionable: Favor debt deleveraging plays; monitor merger closes and dividend records for near-term pops.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — February 27, 2026

Across 23 filings from the USA S&P 500 Healthcare stream (with some adjacent financials/REITs), dominant themes include neutral board departures (5/23 filings, e.g., Lifeward, Pulse Biosciences, Western New England), Nasdaq compliance threats in biotechs (4/23, Jupiter Neurosciences, Ensysce Biosciences, CIMG, Avidity Biosciences), and limited financial disclosures showing one standout positive (Precipio's 30% YoY revenue growth to $24M, EBITDA inflection to +$1.23M). Period-over-period trends are sparse but highlight Precipio's outperformance with 23% Q4 revenue growth and positive adjusted EBITDA ($0.95M vs $0.40M prior), contrasting Disc Medicine's negative restructuring (20% workforce cut, $2M Q1 charges post-FDA setback). Capital allocation features steady dividends (Triumph Financial $0.44525/depositary share payable Mar 30) and ATM equity raises (Bridgewater $50M, FrontView $75M), signaling liquidity needs amid compliance risks. Portfolio-level patterns reveal biotech vulnerability to delisting (materiality 9/10 average), mixed AGM support (Jewett-Cameron), and high-risk M&A/change-of-control (Avidity). Most critical: Biotech delisting cascades could pressure sector liquidity; actionable now via short-term trades on compliance deadlines (Aug 2026) and Precipio's April catalyst.

11 high priority 12 medium 23 total filings
· daily

S&P 500 Energy Sector SEC Filings — February 26, 2026

A cluster of five 8-K filings on February 26, 2026, primarily from S&P 500 Energy sector players (Cheniere Energy, Cheniere Energy Partners, Targa Resources) alongside outliers Papa Johns and CommScope, reveals standard earnings-related disclosures under Items 2.02 and 9.01 with uniformly neutral sentiment and low risk levels. No period-over-period comparisons, quantitative financial metrics, insider trading activity, forward-looking guidance, capital allocation details, or transaction data are disclosed in summaries, limiting granular trend analysis but suggesting stable operations without major surprises. Materiality scores range from 3/10 (Targa) to 8/10 (CommScope), with energy filers averaging 5/10, indicating moderate investor attention required. Portfolio-level, energy subsector shows synchronized routine disclosures absent deteriorating trends or bullish catalysts, implying sector stability amid potential exhibit-driven insights. Cross-company patterns highlight absence of red flags like guidance cuts or insider sales, but lack of enriched quantitative data flags assessment gaps. Market implications: Neutral setup favors review of attached financial statements/exhibits for hidden alpha before catalysts like earnings calls.

5 medium 5 total filings